-
Takeda Takhzyro Approved in Japan to Prevent Hereditary Angioedema
Time of Update: 2022-05-22
CompileDravenOn March 28, the Japanese Ministry of Health approved Takeda Takhzyro (lanadelumab) 300mg subcutaneous injection as a preventive treatment drug for Japanese patients over 12 years old with hereditary angioedema (HAE) .
These studies demonstrate the efficacy and safety of Takhzyro as a preventive treatment for HAE .
-
How to adjust for lack of energy and easy fatigue?
Time of Update: 2022-05-22
Among them, 21 gold vitamin times + 2nd grade multivitamin and mineral tablets for adult men and women contain 18 kinds of nutrients to supplement daily nutritional needs.
-
Tumours are full of tricks, but bypass the sniper immune cell combination therapy to kill the tumor with a two-pronged approach
Time of Update: 2022-05-22
In a mouse model of ovarian cancer, the researchers used both EPA and purinoceptor antagonists, and the results greatly increased the proliferation of T cells, restoring their ability to kill tumors .
-
The world's first FRα ADC is expected to submit an FDA Biologics License Application in March
Time of Update: 2022-05-22
On March 20, 2022, Huadong Medicine issued an announcement stating that ImmunoGen, a wholly-owned subsidiary of the company’s Sino-US Huadong-US partner, announced that its organization developed a new class 1 biological drug for the treatment of ovarian cancer, Mirvetuximab Soravtansine (IMGN853, referred to as "" Mirvetuximab") full study results of the US pivotal single-arm clinical trial ("SORAYA trial"): the trial has met the primary endpoint, with a confirmed objective response rate (ORR) of 32.
-
Study reveals molecular mechanism underlying altered gene expression in the brains of Alzheimer's patients
Time of Update: 2022-05-22
Now, in a study titled "Multi-transcriptomic analysis points to early organelle dysfunction in human astrocytes in Alzheimer's disease" published in the international journal Neurobiology of Disease, scientists from Spain analyzed data from nearly 800 deceased individuals.
-
21 Which one of Jinweita and Shancun is better?
Time of Update: 2022-05-22
21 Jinweita and Shancun, which have a large sales share in the market, which one is better?Relevant experts said that when choosing nutritional supplements, it is recommended to start with your own actual situation and needs .
-
Science: Revealing that intracellular calcium release plays a key role in synaptic plasticity
Time of Update: 2022-05-22
The relevant research results were published in the journal Science on March 18, 2022, with the title of "Compartment-specific tuning of dendritic feature selectivity by intracellular Ca2+ release" .
-
Science: Revealing how methane-oxidizing bacteria convert methane into fuel
Time of Update: 2022-05-22
In a new study, researchers from Northwestern University discovered the key structures that drive the process by studying the enzymes that methane-oxidizing bacteria use to catalyze this complex reaction .
-
AstraZeneca's Monalizumab and Oleclumab Injection for Injection have been approved for clinical use
Time of Update: 2022-05-22
On March 17, 2022, the CDE official website showed that AstraZeneca was approved for clinical use with Monalizumab and Oleclumab Injection for injection . Both drugs are indicated for the treatment
-
Increase human healthy lifespan by 10 years?
Time of Update: 2022-05-22
A few days ago, Retro Biosciences stepped out of stealth mode and announced the completion of a $180 million financing .
Cell reprogramming studies are expected to move toward clinical proof-of-concept within the next four years .
-
Axsome, a dual-mechanism drowsiness therapy, has been awarded over US$50 million to expand its neuroscience pipeline
Time of Update: 2022-05-22
On March 28, 2022, Axsome Therapeutics announced a definitive agreement with Jazz Pharmaceuticals to acquire Sunosi (solriamfetol) .
Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) that helps maintain excessive daytime sleepiness (EDS) in adults with narcolepsy or obstructive sleep apnea (OSA) awake state .
-
FDA rejects approval of AstraZeneca's new application for Fasenra
Time of Update: 2022-05-22
Recently, the FDA issued a Complete Response Letter (Complete Response Letter) to AstraZeneca Fasenra's application for the treatment of nasal polyps, and rejected the application because the results of the Phase III trial OSTRO data were not convincing enough .
-
New research in the sub-journal of Nature reveals the regulatory mechanism of hematopoietic stem cells entering the bone marrow for the first time
Time of Update: 2022-05-22
▲The huge difference between hematopoietic stem cells and bone marrow microenvironment between embryonic and adulthood (Image source: Reference [1])The experimental results revealed that the bone artery is the key microenvironmental cell in the embryonic stage .
-
Research and development of a new generation of polypeptide antibiotics for super bacterial infection
Time of Update: 2022-05-22
This is the first new polypeptide drug with a high therapeutic index (Therapeutic index) against multidrug-resistant Gram-negative bacteria since polymyxin was first used in clinical treatment more than 60 years ago, and has great potential and application prospects .
-
Mingde Bio's novel coronavirus antigen detection reagent obtains medical device registration certificate
Time of Update: 2022-05-22
This product is used for in vitro qualitative detection of novel coronavirus (2019-nCoV) N antigen in nasal swab/nasopharyngeal swab/oropharyngeal swab samples .
A positive result only indicates that there may be a new coronavirus specific antigen in the sample.
-
For the benefit of patients with respiratory diseases!
Time of Update: 2022-05-22
"▲ The secretion of mucin by airway epithelial cells involves the mechanism of fusion of vesicles with cell membranes under the stimulation of calcium signals.
-
Evusheld approved in EU for pre-exposure prophylaxis of COVID-19 in broad population
Time of Update: 2022-05-22
Evusheld clinical study results include data from the Phase III PROVENT pre-exposure prophylaxis trial, which showed a 77% reduction in the relative risk of symptomatic COVID-19 infection in subjects using Evusheld compared with placebo; median follow-up The 6-month analysis showed an 83% reduction in relative risk of symptomatic COVID-19 infection; protection persisted for at least 6 months .
-
Pfizer's 20-valent pneumococcal polysaccharide conjugate vaccine declares for clinical application in China
Time of Update: 2022-05-22
Article source: Medical Cube InfoAuthor: infoOn April 1, the CDE official website showed that Pfizer's 20-valent pneumococcal polysaccharide conjugate vaccine (PREVNAR 20, PCV20) has been accepted by the State Food and Drug Administration for clinical applications in China .
-
Tengsheng Biopharmaceuticals announced that the National Health Commission has included the combination therapy of ambavirumab/romisevirumab in the "New Coronary Virus Pneumonia Diagnosis and Treatment Program (Trial Version 9)"
Time of Update: 2022-05-22
Ambavirumab/romisevirumab combination therapy is my country's first self-developed anti-new coronavirus drug that has been proven effective in an international multi-center large-sample randomized, double-blind, placebo-controlled studyThe test data of in vitro chimeric virus experiments show that the combination therapy of ambavirumab/romisevirumab maintains neutralizing activity on the main variants of the new coronavirus that have received widespread attention, such as Omicron, Delta, and Delta+.
-
"Science" cover is heavy!
Time of Update: 2022-05-22
This week, in six papers simultaneously online in the journal Science, an international research team called the Telomere-to-Telomere Consortium (T2T) announced the completion of the latest human reference genome (named T2T-CHM13), Includes seamless assembly of all 22 autosomes and X chromosomes .
